List of Excipients in Branded Drug DIPYRIDAMOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Carilion Materials Management	DIPYRIDAMOLE	dipyridamole	68151-2996	ACACIA
Carilion Materials Management	DIPYRIDAMOLE	dipyridamole	68151-2996	ALUMINUM OXIDE
Carilion Materials Management	DIPYRIDAMOLE	dipyridamole	68151-2996	CARNAUBA WAX
Carilion Materials Management	DIPYRIDAMOLE	dipyridamole	68151-2996	D&C RED NO. 30
Carilion Materials Management	DIPYRIDAMOLE	dipyridamole	68151-2996	D&C YELLOW NO. 10

Generic Drugs Containing DIPYRIDAMOLE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	dipyridamole	0115-1070	HYPROMELLOSES
Amneal Pharmaceuticals of New York LLC	dipyridamole	0115-1070	LACTOSE MONOHYDRATE
Amneal Pharmaceuticals of New York LLC	dipyridamole	0115-1070	MAGNESIUM STEARATE
Amneal Pharmaceuticals of New York LLC	dipyridamole	0115-1070	POLYETHYLENE GLYCOL
Amneal Pharmaceuticals of New York LLC	dipyridamole	0115-1070	POVIDONE

What are the Most Frequently-Used Excipients in DIPYRIDAMOLE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
1	ANHYDROUS LACTOSE
1	CARNAUBA WAX
2	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE

Dipyridamole Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Dipyridamole is a mature, low-cost antiplatelet with limited active-ingredient patent protection and substantial generic competition. The main commercial opportunity is not a new chemical entity. It is an improved oral delivery system that increases dissolution, controls exposure, reduces gastrointestinal burden, or combines dipyridamole with aspirin in a differentiated fixed-dose product. Excipient selection is central because dipyridamole has poor aqueous solubility and formulation performance can affect bioavailability.

The strongest opportunities are:

• Extended-release and once-daily oral delivery.
• Improved dissolution through particle engineering, wetting agents, polymers, or amorphous systems.
• Fixed-dose aspirin-dipyridamole products with improved tolerability and adherence.
• Lower-cost, regionally manufactured generic products.
• Specialty formulations for patients who cannot reliably swallow conventional capsules or tablets.
• Excipient and contract-development services for generic and 505(b)(2) applicants.

What is dipyridamole and where is it used?

Dipyridamole is a platelet aggregation inhibitor and vasodilator. Oral products are used alone or with aspirin for secondary prevention of ischemic stroke and transient ischemic attack. Intravenous dipyridamole has been used as a coronary vasodilator for myocardial perfusion imaging, although regadenoson and adenosine-based protocols have reduced its commercial importance in that setting.

The major marketed oral products are:

Product	Active ingredients	Dosage form	Principal use
Persantine	Dipyridamole	Immediate-release tablets	Antiplatelet therapy; legacy product
Generic dipyridamole	Dipyridamole	25 mg, 50 mg, and 75 mg tablets in the United States	Antiplatelet therapy
Aggrenox	Aspirin 25 mg plus dipyridamole 200 mg	Extended-release dipyridamole capsule	Secondary stroke prevention
Generic aspirin/extended-release dipyridamole	Aspirin 25 mg plus dipyridamole 200 mg	Extended-release capsule	Secondary stroke prevention

The FDA-approved aspirin/extended-release dipyridamole regimen is one capsule twice daily. The product combines immediate-release aspirin with extended-release dipyridamole, creating two release profiles in one dosage form (Boehringer Ingelheim, 2023; FDA, 2024a).

What excipient properties matter most for dipyridamole?

Dipyridamole is poorly soluble in water. Its dissolution is affected by particle size, crystal form, wetting, gastric pH, and the ability of the formulation to maintain the drug in a dissolved or supersaturated state. These characteristics make excipient selection commercially important even though the molecule itself is generic.

Key formulation objectives are:

1. Increase wettability and dissolution rate.
2. Prevent precipitation after initial solubilization.
3. Maintain consistent drug release across gastrointestinal pH conditions.
4. Avoid excessive food effects.
5. Preserve chemical and physical stability during storage.
6. Enable robust manufacturing at commercial scale.
7. Avoid excipients that create safety, labeling, or bioequivalence complications.

Dipyridamole has weak-base behavior and pH-dependent solubility. Formulators therefore need to evaluate performance in acidic, neutral, and intestinal media rather than relying only on water dissolution.

Which excipients are used in dipyridamole products?

Immediate-release tablets

Immediate-release dipyridamole tablets commonly use conventional oral solid-dose excipients, including:

• Lactose or another soluble filler.
• Microcrystalline cellulose.
• Maize starch or pregelatinized starch.
• Povidone as a binder.
• Crospovidone or sodium starch glycolate as a disintegrant.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate as a lubricant.
• Film-coating polymers, pigments, and plasticizers.

The exact composition varies by manufacturer and strength. FDA labeling identifies inactive ingredients at the product level, but generic manufacturers may use different excipient systems if they demonstrate pharmaceutical equivalence, bioequivalence, and acceptable quality attributes (FDA, 2024b).

For immediate-release products, the main risk is not tablet disintegration. It is achieving sufficiently rapid and reproducible drug dissolution after disintegration. A highly hydrophobic or over-lubricated formulation can produce slow dissolution even when disintegration is within specification.

Extended-release capsules

The extended-release dipyridamole component of Aggrenox is formulated as pellets or beads within a capsule. Multiparticulate systems allow the manufacturer to combine immediate-release aspirin with delayed or extended-release dipyridamole.

Relevant excipient functions include:

Function	Representative excipient classes	Commercial purpose
Pellet core	Sugars, microcrystalline cellulose, starch	Provides a substrate for drug layering
Binder	Povidone, hydroxypropyl cellulose	Adheres drug to the pellet
Wetting or solubilizing agent	Polysorbates, surfactants	Improves contact with gastrointestinal fluid
Release-control coat	Ethylcellulose, methacrylate polymers, hypromellose	Controls dipyridamole release
Pore former	Water-soluble polymers or sugars	Adjusts permeability of the coating
Anti-tack agent	Talc, colloidal silica	Supports coating efficiency
Capsule shell	Gelatin or hypromellose	Provides the final dosage form

The commercial challenge is to release dipyridamole over the intended interval without causing dose dumping, excessive variability, or an unacceptable food effect. The release system must also remain stable during coating, drying, filling, and storage.

What formulation approaches can improve dipyridamole dissolution?

Particle-size reduction

Micronized or nanosized dipyridamole can increase surface area and accelerate dissolution. The approach is relatively direct and may fit a conventional generic development program. Risks include agglomeration, electrostatic handling problems, poor flow, and physical instability.

Particle engineering is most attractive when the developer wants a relatively simple product without introducing a large excipient burden. It may be less defensible as a patent strategy unless combined with a defined particle-size distribution, manufacturing process, or release profile.

Surfactant-assisted formulations

Surfactants can improve wetting and reduce interfacial resistance. Polysorbates, sodium lauryl sulfate, poloxamers, and related agents are possible candidates, subject to dose, tolerability, compatibility, and regulatory precedent.

The principal development risk is that excessive surfactant can alter gastrointestinal tolerability or create stability problems. Surfactant selection should be linked to a demonstrated dissolution benefit rather than used as a routine processing aid.

Amorphous solid dispersions

Polyvinylpyrrolidone, copovidone, hydroxypropyl methylcellulose acetate succinate, and related polymers can maintain dipyridamole in a higher-energy amorphous state. This can increase apparent solubility and dissolution.

The principal risk is recrystallization during storage. A successful program requires solid-state characterization, including differential scanning calorimetry, powder X-ray diffraction, moisture sorption, and long-term stability.

Lipid or self-emulsifying systems

Lipid-based systems can improve dispersion of poorly soluble drugs. They may be useful in softgels, liquid-filled capsules, or self-emulsifying formulations. Their commercial use is constrained by capsule compatibility, oxidation, fill weight, manufacturing complexity, and food-effect considerations.

pH-modified systems

Acidifying or buffering excipients can increase dissolution in the stomach or at the tablet surface. The strategy must be carefully controlled because local pH modification may produce variable performance after gastric emptying.

Multiparticulate modified-release systems

Multiparticulates can improve dose distribution, reduce sensitivity to localized gastrointestinal conditions, and allow more flexible release design. They are technically stronger than simple matrix tablets but require more complex manufacturing and analytical controls.

What formulation patents could protect a dipyridamole product?

The original dipyridamole compound and the principal branded formulations are legacy assets. The commercial value of a new patent would therefore depend on a specific formulation or manufacturing limitation.

Potential claim categories include:

• A defined particle-size distribution.
• A specified amorphous or crystalline form.
• A solid dispersion with a particular polymer ratio.
• A multiparticulate pellet with defined coating layers.
• A controlled-release profile.
• A fixed-dose aspirin-dipyridamole composition.
• Reduced food effect or improved pharmacokinetic consistency.
• A manufacturing process that prevents recrystallization.
• A taste-masked liquid or orally disintegrating dosage form.
• A low-dose formulation for a defined patient population.

A broad claim covering “dipyridamole with a pharmaceutically acceptable excipient” would face substantial validity and obviousness risk because the drug has been formulated for decades. Stronger claims would need a measurable technical distinction, such as a defined dissolution profile, stability threshold, particle attribute, release mechanism, or pharmacokinetic result.

Patent and Orange Book position

The principal patent and exclusivity barriers associated with dipyridamole and aspirin/extended-release dipyridamole are generally exhausted. The Orange Book lists approved products, reference products, therapeutic-equivalence information, and any applicable listed patents or exclusivity data (FDA, 2024c). Legacy patents should be checked by product and strength because listings can differ between immediate-release dipyridamole and combination extended-release products.

A new formulation could receive patent protection even when the underlying drug is off patent. That protection would cover only the claimed formulation, method, or manufacturing process. It would not block conventional dipyridamole tablets or non-infringing aspirin/dipyridamole products.

When does dipyridamole lose exclusivity?

Dipyridamole lost meaningful chemical exclusivity decades ago. Generic immediate-release products are established in major markets. The aspirin/extended-release dipyridamole combination also has generic competition.

The relevant exclusivity framework is:

Asset	Exclusivity position	Commercial effect
Dipyridamole active ingredient	Expired	Conventional generic entry is available
Immediate-release tablets	Mature generic market	Price competition is substantial
Aspirin/extended-release dipyridamole	Generic competition established	Differentiation requires cost, supply, or formulation advantages
New reformulation	Potentially patentable	Protection depends on narrow technical claims
New indication	Potential method-of-use protection	Enforcement depends on labeling and induced-infringement facts

A Paragraph IV challenge would be relevant only to a currently listed patent protecting a particular reference product or reformulation. It would not revive exclusivity for dipyridamole as a molecule. For a new 505(b)(2) product, the applicant would need to address listed patents and demonstrate safety and effectiveness using the applicable reference product or literature-supported pathway (FDA, 2024d).

What FDA regulatory pathways are available?

Abbreviated New Drug Application

An ANDA is the most direct route for a conventional dipyridamole tablet or aspirin/extended-release dipyridamole capsule. The applicant must establish pharmaceutical equivalence and bioequivalence to the relevant reference-listed drug.

For modified-release products, development generally requires:

• Comparative dissolution across multiple media.
• Release-profile similarity.
• Pharmacokinetic bioequivalence.
• Assessment of food effects where applicable.
• Control of critical pellet, coating, and capsule attributes.
• Stability data supporting the proposed shelf life.

505(b)(2) application

A 505(b)(2) application may be suitable for a genuinely differentiated product, such as:

• An orally disintegrating dosage form.
• A liquid or suspension.
• A new release profile.
• A new route of administration.
• A product with a clinically supported reduction in dosing frequency.
• A product combining dipyridamole with a new delivery technology.

The commercial case must justify the added development and regulatory expense. A reformulation that only changes inactive ingredients but delivers no meaningful clinical or adherence benefit may not support premium pricing.

European and other international pathways

In Europe, conventional products may proceed through generic or hybrid applications depending on the formulation and clinical data package. A modified-release product may require additional pharmacokinetic or clinical support. Regional excipient acceptability, nitrosamine controls, elemental impurity requirements, and local reference-product availability can affect launch timing.

Which companies are challenging or competing with dipyridamole products?

The competitive field includes:

• Generic manufacturers of dipyridamole tablets.
• Generic manufacturers of aspirin/extended-release dipyridamole capsules.
• Manufacturers of aspirin alone.
• Manufacturers of clopidogrel.
• Manufacturers of aspirin plus clopidogrel regimens.
• Newer antiplatelet products used in overlapping cardiovascular populations.

The main competitive pressure is therapeutic substitution. Physicians may choose clopidogrel or aspirin alone depending on indication, tolerability, guideline preference, cost, and patient adherence. Dipyridamole therefore competes on total treatment value rather than on molecule-level novelty.

For manufacturers, the most defensible commercial advantages are reliable supply, low cost of goods, stable dissolution performance, reduced capsule size, simplified dosing, and differentiated patient usability.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can target dipyridamole developers with platform technologies rather than molecule-specific products.

The most relevant commercial categories are:

1. Solubilization systems. Surfactants, wetting agents, and polymeric solubilizers can support immediate-release and multiparticulate products.

2. Amorphous dispersion platforms. Polymer systems can create a higher-value development opportunity if they maintain stability and improve dissolution.

3. Controlled-release coating systems. Ethylcellulose, methacrylate copolymers, pore formers, and coating process aids are directly relevant to extended-release capsules.

4. Direct-compression systems. Co-processed fillers and disintegrants can reduce manufacturing cost for generic tablets.

5. Capsule and multiparticulate technologies. Pellets, enteric or sustained-release coatings, and capsule-filling systems can support differentiated products.

6. Analytical and development services. Excipient suppliers can provide dissolution modeling, solid-state screening, compatibility studies, and scale-up support.

The strongest customer segment is likely to be mid-sized generic or specialty pharmaceutical companies seeking an ANDA or 505(b)(2) product with a low development burden and defensible product characteristics.

How strong is the patent estate for a new dipyridamole formulation?

A new dipyridamole formulation can have moderate patent strength if it includes a narrow, reproducible technical feature linked to a measurable benefit. Patent strength is weak when the claims rely only on routine excipient substitution.

Patent concept	Likely strength	Reason
Generic tablet with standard excipients	Low	High prior-art exposure
Micronized dipyridamole alone	Low to moderate	Potential obviousness and enablement concerns
Defined amorphous dispersion with stability data	Moderate	Technical effect can support non-obviousness
Multiparticulate release system with defined profile	Moderate to strong	More specific structure and performance
New liquid or orally disintegrating dosage form	Moderate	Usability benefit may support claims
New manufacturing process preventing recrystallization	Moderate	Stronger if process is reproducible and necessary
New clinical indication	Variable	Depends on evidence and claim scope

A patent portfolio should combine formulation claims, process claims, analytical control claims, and method-of-use claims where legally supportable. Relying on a single broad composition claim creates avoidable freedom-to-operate risk.

What generic launch risks exist?

The principal launch risks are commercial and technical rather than molecule-level patent risks.

Technical risks

• Failure to match the reference dissolution profile.
• Excessive food effect.
• Pellet coating variability.
• Dipyridamole recrystallization.
• Inadequate stability under humidity.
• Capsule fill-weight variation.
• Poor scale-up from laboratory coating equipment.
• Incompatibility between dipyridamole and surfactants or polymers.

Regulatory risks

• Incorrect reference-product selection.
• Incomplete modified-release bioequivalence package.
• Inadequate justification for excipient differences.
• Unresolved nitrosamine, elemental impurity, or extractables concerns.
• Labeling differences affecting substitution or interchangeability.

Commercial risks

• Low reimbursement and limited pricing power.
• Substitution by clopidogrel or aspirin.
• Small market size relative to development costs.
• Supply-chain concentration for specialized polymers or coating materials.
• Low tolerance among payers for premium pricing on an old molecule.

How does dipyridamole compare with competing antiplatelet drugs?

Product	Main differentiation	Formulation opportunity	Competitive position
Dipyridamole immediate-release	Low-cost generic	Dissolution and tablet usability	Mature, price-driven
Aspirin/extended-release dipyridamole	Fixed-dose combination and extended release	Release control, adherence, tolerability	Differentiated but generic
Clopidogrel	Once-daily antiplatelet therapy	Conventional solid dose	Strong therapeutic substitute
Aspirin	Low cost and broad familiarity	Low-cost delivery formats	Primary price competitor
Ticagrelor or prasugrel	Potent antiplatelet effect in selected settings	Less relevant excipient opportunity	Higher-cost, indication-specific competitors

The principal weakness of dipyridamole is that the product can require twice-daily administration and may cause headache or gastrointestinal intolerance. A formulation that improves adherence or tolerability has a clearer commercial rationale than a formulation that only modestly accelerates dissolution.

What revenue exposure should investors and licensors assess?

Revenue exposure is concentrated in the aspirin/extended-release dipyridamole segment rather than in immediate-release dipyridamole tablets. The opportunity is generally a stable, mature generic market, not a high-growth branded market.

Key diligence measures include:

• Prescription volume by strength and dosage form.
• Net price after payer discounts.
• Number of approved generic suppliers.
• Back-order and shortage history.
• API supplier concentration.
• Cost and availability of release-control excipients.
• Substitution rates against clopidogrel and aspirin.
• Litigation or regulatory history for the reference product.
• Reimbursement treatment by country.
• Manufacturing complexity and expected gross margin.

A low-cost manufacturer with reliable supply may achieve better returns than a developer pursuing an expensive reformulation with uncertain premium pricing.

What manufacturing and intellectual-property barriers matter most?

The main manufacturing barrier is reproducible dissolution at scale. For multiparticulate products, the critical operations include drug layering, polymer coating, drying, curing, pellet classification, and capsule filling.

Important process controls include:

• Particle-size distribution of dipyridamole.
• Spray rate and atomization conditions.
• Inlet and product temperature.
• Coating weight gain.
• Residual solvent or moisture.
• Pellet friability.
• Capsule fill-weight uniformity.
• Dissolution at multiple pH values.
• Stability of the solid-state form.

The highest-value intellectual property usually lies in the interaction between composition and process. A formulation that cannot be manufactured consistently has limited licensing value even if the patent claims are broad.

Key Takeaways

• Dipyridamole is an established generic drug with minimal remaining molecule-level exclusivity.
• Poor aqueous solubility makes excipient and particle engineering commercially relevant.
• Immediate-release tablets offer a low-cost generic opportunity but limited patent differentiation.
• Aspirin/extended-release dipyridamole capsules provide the stronger platform for formulation innovation.
• Amorphous dispersions, surfactant systems, multiparticulates, and controlled-release coatings are the principal technical options.
• New patent value depends on narrow, measurable formulation or process advantages.
• ANDA development is appropriate for conventional products; 505(b)(2) is more suitable for meaningful delivery or usability improvements.
• The commercial market is mature and price-sensitive, with clopidogrel and aspirin as major therapeutic substitutes.
• Manufacturing consistency, supply reliability, and cost of goods are more important than broad molecule-level patent claims.
• Excipient suppliers can capture value through solubilization, solid dispersion, coating, pelletization, and development-service platforms.

FAQs

Can dipyridamole be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet could improve administration for patients with dysphagia, but the formulation must address the drug’s poor dissolution and bitter or unpleasant taste. Taste masking, rapid dispersion, and bioequivalence would determine commercial feasibility.

Is a liquid dipyridamole product commercially attractive?

A liquid product could serve pediatric, geriatric, or dysphagic patients. Its main challenges are physical stability, dose uniformity, microbial control, taste, and the need to prevent precipitation during storage.

Which excipient is most important for extended-release dipyridamole?

No single excipient determines performance. The release-control polymer, pellet structure, coating weight, surfactant system, and drug-loading process operate as an integrated system. Polymer selection and coating uniformity usually have the greatest effect on release behavior.

Can a new dipyridamole formulation qualify for market exclusivity?

Potentially. A qualifying new formulation may receive patent protection, and a 505(b)(2) product may obtain regulatory exclusivity in appropriate circumstances. The protection would apply to the new formulation or indication, not to conventional dipyridamole products.

Is dipyridamole API supply a major barrier to market entry?

Usually not at the molecule level. The greater risks are API quality consistency, impurity control, particle-size reproducibility, and reliable supply of specialized polymers, coating materials, or multiparticulate manufacturing capacity.

References

Boehringer Ingelheim Pharmaceuticals, Inc. (2023). Aggrenox (aspirin and extended-release dipyridamole) prescribing information. U.S. Food and Drug Administration.

U.S. Food and Drug Administration. (2024a). Aggrenox: Aspirin and extended-release dipyridamole capsules, prescribing information. DailyMed.

U.S. Food and Drug Administration. (2024b). Dipyridamole tablets, prescribing information. DailyMed.

U.S. Food and Drug Administration. (2024c). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

U.S. Food and Drug Administration. (2024d). Applications covered by section 505(b)(2). https://www.fda.gov